Anika Therapeutics

Anika Therapeutics develops, manufactures and commercializes therapeutic products for tissue protection, healing, and repair. The Company is committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger and remain active. 
Anika offers a broad spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care and skin rejuvenation. The Company's proprietary technology is based on hyaluronic acid, a naturally occurring polymer found throughout the body vital for proper joint health and tissue function. Its products include MONOVISC®, ORTHOVISC®, and ORTHOVISC® mini used in the treatment of osteoarthritis; HYVISC® used in the treatment of equine osteoarthritis; ELEVESS® cosmetic dermal filler with lidocaine; ANIKAVISC® viscoelastic for ophthalmic surgery; INCERT®-S anti-adhesion surgical gel; and next generation products for joint health, advanced wound care and other applications.
At Anika, they believe that an individual’s feelings about their age are driven by perceptions about the state of their body.
Company Growth (employees)
Type
Public
HQ
Bedford, US
Founded
1992
Size (employees)
122 (est)
Anika Therapeutics was founded in 1992 and is headquartered in Bedford, US

Anika Therapeutics Office Locations

Anika Therapeutics has offices in Bedford and Ponte Fabbrica
Bedford, US (HQ)
32 Wiggins Ave
Ponte Fabbrica, IT
3 Via Ponte della Fabbrica

Anika Therapeutics Data and Metrics

Anika Therapeutics Financial Metrics

Anika Therapeutics's revenue was reported to be $23.4 m in Q1, 2017
USD

Revenue (Q1, 2017)

23.4 m

Net income (Q1, 2017)

5.5 m

EBIT (Q1, 2017)

8 m

Market capitalization (17-Aug-2017)

792.5 m

Cash (31-Mar-2017)

119.4 m
Anika Therapeutics's current market capitalization is $792.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

75.1 m105.6 m93 m103.4 m

Revenue growth, %

41%(12%)11%

Cost of goods sold

22.8 m20.9 m21.1 m24 m

Gross profit

52.3 m84.7 m71.9 m79.4 m

Gross profit Margin, %

70%80%77%77%

Operating expense total

19.7 m44.1 m44.9 m52.8 m

EBIT

32.6 m61.4 m48.1 m50.6 m

EBIT margin, %

43%58%52%49%

Interest income

127.2 k58.1 k120 k263 k

Pre tax profit

32.5 m61.5 m48.3 m50.9 m

Income tax expense

11.9 m23.2 m17.5 m18.3 m

Net Income

20.6 m38.3 m30.8 m32.5 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

26.3 m22.1 m15.5 m22.9 m23.7 m22.3 m26.6 m25.8 m23.4 m

EBIT

15.2 m10.3 m5.5 m12.4 m13.1 m10.7 m13.5 m13.7 m8 m

EBIT margin, %

58%47%35%54%55%48%51%53%34%

Interest income

5.9 k9.9 k

Pre tax profit

15.2 m10.3 m5.5 m12.5 m13.2 m10.8 m13.5 m13.8 m8.1 m

Net Income

9.3 m6.2 m3.5 m7.8 m8.4 m6.9 m8.6 m9 m5.5 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

63.3 m100.2 m110.7 m104.3 m

Inventories

11 m12.4 m14.9 m16 m

Current Assets

94.6 m139 m176.4 m170.4 m

PP&E

52.4 m53.6 m40.1 m52.3 m

Goodwill

9.4 m8.3 m7.5 m7.2 m

Total Assets

156 m194 m235.7 m240.2 m

Accounts Payable

2.8 m1.2 m8.3 m2.3 m

Current Liabilities

9.3 m6 m17.3 m8.8 m

Additional Paid-in Capital

70.6 m77.5 m81.7 m61.7 m

Retained Earnings

66.6 m104.9 m135.7 m168.2 m

Total Equity

135.6 m178.1 m210.8 m222.8 m

Financial Leverage

1.2 x1.1 x1.1 x1.1 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

84.9 m71.8 m99.8 m103.9 m108.5 m92.8 m89.1 m98 m119.4 m

Inventories

13.9 m13.6 m12.5 m11.7 m12.1 m15.8 m17.3 m18 m16.2 m

Current Assets

119.5 m128.7 m145.9 m155.7 m168.3 m147.9 m154.6 m161.1 m177.1 m

PP&E

31.5 m33.8 m46.8 m49.2 m51.1 m51.6 m

Goodwill

9.4 m8.7 m7.4 m7.6 m7.7 m7.8 m7.6 m7.7 m7.3 m

Total Assets

179.1 m185.5 m197.7 m208 m222.9 m214.5 m222.7 m231.1 m247.4 m

Accounts Payable

2.2 m1.2 m1.8 m1.7 m2.2 m3.3 m3.3 m1.9 m6.1 m

Current Liabilities

7.3 m6.4 m6.2 m8 m13.2 m10.9 m10.5 m7.6 m10.2 m

Additional Paid-in Capital

73.2 m76.1 m80 m80.5 m81.1 m58.5 m59.5 m60.4 m63.7 m

Retained Earnings

90.9 m97.1 m108.4 m116.2 m124.6 m142.6 m151.2 m160.1 m173.2 m

Total Equity

190.6 m199.8 m195.4 m204.4 m214.5 m230 m

Financial Leverage

1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

20.6 m38.3 m30.8 m32.5 m

Depreciation and Amortization

4.8 m4.7 m3.8 m3.7 m

Accounts Receivable

2.4 m897.6 k(5 m)(6.2 m)

Inventories

(2.8 m)(2 m)(2.9 m)(1.7 m)

Accounts Payable

622.9 k(749.6 k)5.6 m(5.1 m)

Cash From Operating Activities

25.2 m40 m39.1 m23.8 m

Purchases of PP&E

(440.9 k)(1.6 m)(9.2 m)

Cash From Investing Activities

(253.2 k)(8.3 m)(30.2 m)(6.8 m)

Cash From Financing Activities

(5.7 m)5.3 m1.9 m(23.3 m)

Interest Paid

126 k126 k

Income Taxes Paid

9.8 m13.8 m12.7 m22.8 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

9.3 m6.2 m3.5 m7.8 m8.4 m6.9 m8.6 m9 m5.5 m

Inventories

13.9 m13.6 m12.5 m11.7 m12.1 m15.8 m17.3 m18 m16.2 m

Accounts Payable

2.2 m1.2 m1.8 m1.7 m2.2 m3.3 m3.3 m1.9 m6.1 m
USDY, 2017

Revenue/Employee

191.7 k

Financial Leverage

1.1 x

Anika Therapeutics Operating Metrics

FY, 2016

Patents (US)

21

Patents (foreign)

151

Patents Licensed

95

Patents Pending

14

    Anika Therapeutics Market Value History

    Traffic Overview of Anika Therapeutics

    Anika Therapeutics Online and Social Media Presence

    Anika Therapeutics Company Life and Culture

    You may also be interested in